Current status and research progress of metal stent combined with intraluminal antineoplastic technique in treatment of malignant biliary obstruction

doi:10.3877/cma.j.issn.2095-5782.2019.02.015

Abstract

Abstract:

Malignant biliary obstruction is a biliary obstructive disease caused directly or indirectly by malignant tumors. Its main clinical manifestations are hyperbilirubinemia and bile duct dilatation. More than 50% of patients are in advanced stage of treatment and have lost the opportunity for radical surgery. Percutaneous transhepatic biliary stenting can relieve biliary obstruction and is an effective palliative treatment. At present, biliary metal stent implantation combined with endoluminal anti-tumor techniques, such as drug-eluting stent, intra-luminal brachytherapy, intracavitary ablation and photodynamic therapy, are emerging in clinical applications for the treatment of malignant biliary obstruction. Now according to the latest literatures at home and abroad, the current progress of interventional treatment of biliary metal stents for malignant biliary obstruction are summarized.

Key words: Cholangiocarcinoma, Malignant biliary obstruction, Metallic stents, Brachytherapy, Drug-eluting stents, Catheter ablation, Photochemotherapy

Jianjian Chen, Yuan Yao, Xueliang Zhou, Dechao Jiao, Xinwei Han. Current status and research progress of metal stent combined with intraluminal antineoplastic technique in treatment of malignant biliary obstruction[J]. Chinese Journal of Interventional Radiology(Electronic Edition), 2019, 07(02): 163-167.

/ / Recommend

Add to citation manager EndNote|Ris|BibTeX

URL: https://zhjrfsxdzzz.cma-cmc.com.cn/EN/10.3877/cma.j.issn.2095-5782.2019.02.015

https://zhjrfsxdzzz.cma-cmc.com.cn/EN/Y2019/V07/I02/163

References 41

[1]	Razumilava N, Gores GJ. Cholangiocarcinoma[J]. The Lancet，2014，383(9935):2168-2179.
[2]	Banales JM, Cardinale V, Carpino G，et al. Expert consensus document：Cholangiocarcinoma：current knowledge and future perspectives consensus statement from the European Network for the Study of Cholangiocarcinoma（ENS-CCA）[J]. Nat Rev Gastroenterol Hepatol，2016，13(5):261-280.
[3]	Bismuth H, Castaing D, Traynor O. Resection or palliation：priority of surgery in the treatment of hilar cancer[J]. World J Surg，1988，12(1):39-47.
[4]	Khan SA, Thomas HC, Davidson BR，et al. Cholangiocarcinoma[J]. The Lancet，2005，366(9493):1303-1314.
[5]	Larghi A, Tringali A, Lecca PG，et al. Management of hilar biliary strictures[J]. Am J Gastroenterol，2008，103(2):458-473.
[6]	Speer AG, Cotton PB, Russell RC，et al. Randomised trial of endoscopic versus percutaneous stent insertion in malignant obstructive jaundice[J]. Lancet，1987，2(8550):57-62.
[7]	Kim JH. Endoscopic stent placement in the palliation of malignant biliary obstruction[J]. Clin Endosc，2011，44(2):76-86.
[8]	Kanasaki S, Furukawa A, Kane T，et al. Polyurethane-covered Nitinol Strecker stents as primary palliative treatment of malignant biliary obstruction[J]. Cardiovasc Intervent Radiol，2000，23(2):114-120.
[9]	Almadi M A, Barkun AN, Martel M. No benefit of covered vs uncovered self-expandable metal stents in patients with malignant distal biliary obstruction：a meta-analysis[J]. Clin Gastroenterol Hepatol，2013，11(1):27-37.
[10]	Yang MJ, Kim JH, Yoo BM，et al. Partially covered versus uncovered self-expandable nitinol stents with anti-migration properties for the palliation of malignant distal biliary obstruction：A randomized controlled trial[J]. Scand J Gastroenterol，2015，50(12):1490-1499.
[11]	隋守光，王滨，曹贵文. 192Ir胆道腔内放射在肝门部胆管癌治疗中的应用[J].潍坊医学院学报，2007，29(1):91-94.
[12]	李文会，罗剑钧，戴真煜，等.腔内近距离放疗联合及支架植入治疗恶性胆道梗阻[J].介入放射学杂志，2015，24(3):215-218.
[13]	Takahashi Y, Ito A, Sumida I，et al. Dosimetric consideration of individual 125I source strength measurement and a large-scale comparison of that measured with a nominal value in permanent prostate implant brachytherapy[J]. Radiat Med，2006，24(10):675-679.
[14]	Wang ZM, Liu Y, Liu FJ，et al. Clinical efficacy of CT-guided iodine-125 seed implantation therapy in patients with advanced pancreatic cancer[J]. Eur Radiol，2010，20(7):1786-1791.
[15]	Trombetta MG, Colonias A, Makishi D，et al. Tolerance of the aorta using intraoperative iodine-125 interstitial brachytherapy in cancer of the lung[J]. Brachytherapy，2008，7(1):50-54.
[16]	Chen Y, Wang XL, Yan ZP，et al. The use of 125I seed strands for intraluminal brachytherapy of malignant obstructive jaundice[J]. Cancer Biother Radiopharm，2012，27(5):317-323.
[17]	陈旭，朱光宇，滕皋军，等.胆管内照射支架应用的实验研究[J].介入放射学杂志，2012，21(5):399-404.
[18]	郭金和，朱光宇，朱海东，等.胆管内照射支架的研制及临床应用的初步结果[J].中华医学杂志，2011，91(33):2310-2313.
[19]	Zhu HD, Guo JH, Zhu GY，et al. A novel biliary stent loaded with （125）I seeds in patients with malignant biliary obstruction：preliminary results versus a conventional biliary stent[J]. J Hepatol，2012，56(5):1104-1111.
[20]	Zhu HD, Guo JH, Huang M，et al. Irradiation stents vs. conventional metal stents for unresectable malignant biliary obstruction：A multicenter trial[J]. J Hepatol，2018，68(5):970-977.
[21]	Lee DK. Drug-eluting stent in malignant biliary obstruction[J]. J Hepatobiliary Pancreat Surg，2009，16(5):628-632.
[22]	张明明，肖宏生，沈洋，等.丝裂霉素C药物洗脱支架用于胆管良性狭窄治疗的实验研究[J].中华消化内镜杂志，2013，30(7):389-393.
[23]	张明明.曲安奈德胆管洗脱支架的制作及其在胆管良性狭窄中的应用[D].苏州：苏州大学，2013.
[24]	Lee SS, Shin JH, Han JM，et al. Histologic influence of paclitaxel-eluting covered metallic stents in a canine biliary model[J]. Gastrointest Endosc，2009，69(6):1140-1147.
[25]	Song TJ, Lee SS, Yun SC，et al. Paclitaxel-eluting covered metal stents versus covered metal stents for distal malignant biliary obstruction：A prospective comparative pilot study[J]. Gastrointest Endosc，2011，73(4):727-733.
[26]	Jang SI, Kim JH, Kim M，et al. Porcine feasibility and safety study of a new paclitaxel-eluting biliary stent with a Pluronic-containing membrane[J]. Endoscopy，2012，44(9):825-831.
[27]	周瑜，吴志远，丁晓毅.不可逆电穿孔消融治疗胰腺癌的现状与展望[J].中华介入放射学电子杂志，2017，5(3):194-198.
[28]	Li X, Fan WJ, Zhang L，et al. CT-guided percutaneous microwave ablation of adrenal malignant carcinoma：preliminary results[J]. Cancer，2011，117(22):5182-5188.
[29]	Wang JF, Zhao LZ, Zhou CG，et al. Percutaneous intraductal radiofrequency ablation combined with biliary stent placement for nonresectable malignant biliary obstruction improves stent patency but not survival[J]. Medicine（Baltimore），2016，95(15):e3329.
[30]	Duan XH, Wang YL, Han XW，et al. Intraductal radiofrequency ablation followed by locoregional tumor treatments for treating occluded biliary stents in non-resectable malignant biliary obstruction：A single-institution experience[J]. PLoS One，2015，10(8):e0134857.
[31]	Steel AW, Postgate AJ, Khorsandi S，et al. Endoscopically applied radiofrequency ablation appears to be safe in the treatment of malignant biliary obstruction[J]. Gastrointest Endosc，2011，73(1):149-153.
[32]	Mizandari M, Kumar J, Pai M，et al. Interventional radiofrequency ablation：A promising therapeutic modality in the management of malignant biliary and pancreatic duct obstruction[J]. J Cancer，2018，9(4):629-637.
[33]	Hansler J, Wissniowski TT, Schuppan D，et al. Activation and dramatically increased cytolytic activity of tumor specific T lymphocytes after radio-frequency ablation in patients with hepatocellular carcinoma and colorectal liver metastases[J]. World J Gastroenterol，2006，12(23):3716-3721.
[34]	Strand DS, Cosgrove ND, Patrie JT，et al. ERCP-directed radiofrequency ablation and photodynamic therapy are associated with comparable survival in the treatment of unresectable cholangiocarcinoma[J]. Gastrointest Endosc，2014，80(5):794-804.
[35]	Tal AO, Vermehren J, Friedrich-Rust M，et al. Intraductal endoscopic radiofrequency ablation for the treatment of hilar non-resectable malignant bile duct obstruction[J]. World J Gastrointest Endosc，2014，6(1):13-19.
[36]	Tian G, Zhao QY, Chen F，et al. Ablation of hepatic malignant tumors with irreversible electroporation：A systematic review and meta-analysis of outcomes[J]. Oncotarget，2017，8(4):5853-5860.
[37]	Ueshima E, Schattner M, Mendelsohn R，et al. Transmural ablation of the normal porcine common bile duct with catheter-directed irreversible electroporation is feasible and does not affect duct patency[J]. Gastrointest Endosc，2018，87(1):300. e1-300300.e6.
[38]	Martin EK, Bhutiani N, Egger ME，et al. Safety and efficacy of irreversible electroporation in the treatment of obstructive jaundice in advanced hilar cholangiocarcinoma[J]. HPB（Oxford），2018，20(11):1092-1097.
[39]	Lee TY, Cheon YK, Shim CS，et al. Photodynamic therapy prolongs metal stent patency in patients with unresectable hilar cholangiocarcinoma[J]. World J Gastroenterol，2012，18(39):5589-5594.
[40]	Moole H, Tathireddy H, Dharmapuri S，et al. Success of photodynamic therapy in palliating patients with nonresectable cholangiocarcinoma：A systematic review and meta-analysis[J]. World J Gastroenterol，2017，23(7):1278-1288.
[41]	Bae BC, Yang SG, Jeong S，et al. Polymeric photosensitizer-embedded self-expanding metal stent for repeatable endoscopic photodynamic therapy of cholangiocarcinoma[J]. Biomaterials，2014，35(30):8487-8495.

Please choose a citation manager

Content to export